Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990.Martin J. van den Bent, Anna K. Nowak, Marc Sanson et al.|Journal of Clinical Oncology|2025Cited by 5
CTNI-14. RADIOTHERAPY VERSUS TMZ FOR HIGH-RISK LOW-GRADE GLIOMA. FINAL RESULTS AFTER MEDIAN FOLLOW-UP OF 13 YEARS OF PHASE III EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) STUDYBrigitta G. Baumert, Roger Stupp, Monika E. Hegi et al.|Neuro-Oncology|2024Cited by 4